Direct-to-consumer (DTC) Laboratory Testing Market by Application (Genetic Testing {Ancestry, Carrier Status, Disease Risk [Cancer, Neurological, Cardiac]}, Diabetes, COVID, STD, Routine, CBC), Sample Type (Saliva, Urine, Blood)—Global Forecast to 2030

Direct-to-consumer (DTC) Laboratory Testing Market by Application (Genetic Testing {Ancestry, Carrier Status, Disease Risk [Cancer, Neurological, Cardiac]}, Diabetes, COVID, STD, Routine, CBC), Sample Type (Saliva, Urine, Blood)—Global Forecast to 2030

Direct-to-consumer (DTC) Laboratory Testing Market by Application (Genetic Testing {Ancestry, Carrier Status, Disease Risk [Cancer, Neurological, Cardiac]}, Diabetes, COVID, STD, Routine, CBC), Sample Type (Saliva, Urine, Blood)—Global Forecast to 2030

The global DTC laboratory testing market is projected to reach $7.92 billion by 2030, at a CAGR of 10.9% from 2023 to 2030.

Following a comprehensive primary and secondary study and an in-depth analysis of the market scenario, this report provides the key drivers, constraints, challenges, and opportunities of the industry. This market is driven by the increased consumer awareness regarding personal health management. Consumers can order a DTC lab test directly without consulting their healthcare provider and get results, allowing them to monitor & manage their health & wellness.

Furthermore, the growing adoption of telehealth, the rising popularity of DTC laboratory testing in emerging economies, and the increasing penetration of DTC pharmacogenomic testing provide a significant growth opportunity for this market. However, sample integrity and interference issues, regulatory concerns, the lack of reimbursements, and the lack of extensive test portfolios compared to conventional laboratory testing may restrain the growth of this market. Additionally, the concerns regarding the security and privacy of genomic data, misinterpretation of test results, and the lack of professional medical counseling pose a major challenge for the players operating in this market.

Based on application, in 2023, the genetic testing segment is expected to account for the largest share of the DTC laboratory testing market. The genetic testing segment is further segmented into ancestry/genealogy, disease risk assessment, carrier status, and other genetic tests. In 2023, the ancestry/genealogy segment is expected to account for the largest share of the global direct-to-consumer genetic testing market. Factors such as increased consumer interest & curiosity regarding ancestry, technological advancements to make genetic testing accessible, strong advertising & marketing by the companies, high racial diversity and interracial mix in some countries, and the advantages such as convenience & accessibility are driving the growth of this segment.

Based on sample type, in 2023, the blood segment is expected to account for the largest share of the DTC laboratory testing market. The large market share of this segment is attributed to the demand for tests that require blood samples and the advantages of blood samples in obtaining reliable results in a wide range of test portfolios.

An in-depth analysis of the geographical scenario of the global DTC laboratory testing market provides detailed qualitative and quantitative insights for the five major geographies (North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America) along with the coverage of major countries in each region.

In 2023, North America is expected to account for the largest share of the global DTC laboratory testing market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Asia-Pacific is expected to be the fastest-growing region of the global DTC laboratory testing market.

The key players operating in the global DTC laboratory testing market are Quest Diagnostics Incorporated (U.S.), Laboratory Corporation of America Holdings (U.S.), 23andMe Holding Co. (U.S.), Myriad Genetics, Inc. (U.S.), Everlywell, Inc. (U.S.), DirectLabs, LLC. (U.S.), Ancestry.com, LLC (U.S.), MyMedLab, Inc. (U.S.), ANY LAB TEST NOW (U.S.), Thorne HealthTech, Inc. (U.S.), and LetsGetChecked, Inc. (U.S.).

Other than these, there are several regional players such as Color Health, Inc. (U.S), Laboratoire CERBA (France), MyHeritage Ltd. (Israel), Genova Diagnostics Inc. (U.S.), Gene by Gene, Ltd. (U.S.), Metropolis Healthcare Limited (India), Vitagene (U.S.), SRL Limited (India), Hirotsu Bio Science (Japan), Ambry Genetics Corporation (U.S.), Mapmygenome India Limited (India), FamilyTreeDNA (U.S.), Genera (Brazil), Veritas Intercontinental (Spain), Medichecks.com Ltd. (U.K.), EasyDNA (U.S.) (Subsidiary of Genetic Technologies Limited (Australia), Cerascreen Biotech LLC (U.K.), and Living DNA Ltd (U.K.).

Scope of the Report:

DTC Laboratory Testing Market, by Application

Genetic Testing
Ancestry/Genealogy
Disease Risk Assessment
Cancer
Cardiovascular Diseases
Neurological Diseases
Other Diseases

(Note: Disease risk assessment testing for other diseases includes celiac disease, alpha-1 antitrypsin deficiency, factor XI deficiency, glucose-6-phosphate dehydrogenase deficiency, etc.)
Carrier Status
Other Genetic Tests

(Note: The other genetic tests majorly include direct-to-consumer genetic testing for pharmacogenomics, skin care DNA tests, and nutrigenomic testing)
Routine Clinical Testing
Diabetes Testing
COVID-19
Sexually Transmitted Disease Testing
Thyroid Function Testing
Other Applications

(Note: The other applications segment comprises drug screening, infectious disease testing (Tuberculosis, Chicken Pox, Measles, Mumps, Rubella, UTI), allergy testing, fertility, pregnancy and nutritional testing)

DTC Laboratory Testing Market, by Sample Type

Blood
Saliva
Urine
Other Sample Types

(Note: The other sample types segment comprises stool, nasopharyngeal swab, vaginal swab, buccal swab, and semen)

DTC Laboratory Testing Market, by Geography

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe (RoE)
Asia-Pacific (APAC)
Japan
China
India
Rest of APAC (RoAPAC)
Latin America
Middle East & Africa

Direct-to-consumer Laboratory Testing Market - Report Summary

Report Metrics	Details
Years Considered	2021 - 2030
Base Year	2023
Forecast Period	2023-2030
Page Count	209
Units Referenced	Value (USD Million)
Segments/Key Topics	Market by Application, Market by Sample Type, and Market by Geography
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa
Key Companies Mentioned	Quest Diagnostics Incorporated (U.S.), Laboratory Corporation of America Holdings (U.S.), 23andMe Holding Co. (U.S.), Myriad Genetics, Inc. (U.S.), Everlywell, Inc. (U.S.), DirectLabs, LLC. (U.S.), Ancestry.com, LLC (U.S.), MyMedLab, Inc. (U.S.), ANY LAB TEST NOW (U.S.), Thorne HealthTech, Inc. (U.S.), LetsGetChecked, Inc. (U.S.), Color Health, Inc. (U.S), Laboratoire CERBA (France), MyHeritage Ltd. (Israel), Genova Diagnostics Inc. (U.S.), Gene by Gene, Ltd. (U.S.), Metropolis Healthcare Limited (India), Vitagene (U.S.), SRL Limited (India), Hirotsu Bio Science (Japan), Ambry Genetics Corporation (U.S.), Mapmygenome India Limited (India), FamilyTreeDNA (U.S.), Genera (Brazil), Veritas Intercontinental (Spain), Medichecks.com Ltd. (U.K.), EasyDNA (U.S.) (Subsidiary of Genetic Technologies Limited (Australia), Cerascreen Biotech LLC (U.K.), and Living DNA Ltd (U.K.).

FAQs About the Report

What is the scope of the DTC laboratory testing market report?
This market study covers the market sizes & forecasts of the direct-to-consumer laboratory testing market based on application, sample type, and geography. This market study also provides the value analysis of various segments and subsegments of the mice model market at the regional and country levels.

What is the revenue generated from the sale of direct-to-consumer laboratory testing across the globe? At what rate is their demand expected to grow for the next 5–7 years?
The global DTC laboratory testing market is projected to reach $7.92 billion by 2030, at a CAGR of 10.9% during the forecast period.

Which application segment held the major share of the market in 2023?

Based on the application, in 2023, the genetic testing segment is expected to account for the largest share of the DTC laboratory testing market. The rising appeal of DTC genetic testing to explore information regarding family health history and predictive testing, the launch of new DTC genetic tests for new applications, and the increasing curiosity among people in developed countries regarding their ancestry and lineage contribute to the growth of this segment.

Which sample type segment held the major share of the market in 2023?

In 2023, based on the sample type, the blood segment is expected to account for the largest share of the DTC laboratory testing market due to the advantages of the blood samples, such as the availability of a large number of tests, a high convenience of at-home sample collection through a phlebotomist.

What are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the global DTC laboratory testing market?

Easy accessibility of DTC tests, the growing awareness regarding family health history and predictive testing, the increasing demand for early disease diagnosis, and the rising geriatric population that prefers convenient care are expected to propel the global DTC laboratory testing market. Moreover, the increasing adoption of telehealth offers an opportunity to players operating in the DTC laboratory testing market.

Who are the major players operating in the global DTC laboratory testing market?

The key players operating in the global DTC laboratory testing market are Quest Diagnostics Incorporated (U.S.), Laboratory Corporation of America Holdings (U.S.), 23andMe Holding Co. (U.S.), Myriad Genetics, Inc. (U.S.), Everlywell, Inc. (U.S.), DirectLabs, LLC. (U.S.), Ancestry.com, LLC (U.S.), MyMedLab, Inc. (U.S.), ANY LAB TEST NOW (U.S.), Thorne HealthTech, Inc. (U.S.), and LetsGetChecked, Inc. (U.S.).
Other than these, there are several regional players such as Color Health, Inc. (U.S), Laboratoire CERBA (France), MyHeritage Ltd. (Israel), Genova Diagnostics Inc. (U.S.), Gene by Gene, Ltd. (U.S.), Metropolis Healthcare Limited (India), Vitagene (U.S.), SRL Limited (India), Hirotsu Bio Science (Japan), Ambry Genetics Corporation (U.S.), Mapmygenome India Limited (India), FamilyTreeDNA (U.S.), Genera (Brazil), Veritas Intercontinental (Spain), Medichecks.com Ltd. (U.K.), EasyDNA (U.S.) (Subsidiary of Genetic Technologies Limited (Australia), Cerascreen Biotech LLC (U.K.), and Living DNA Ltd (U.K.).

Which regions/countries are likely to offer significant growth opportunities for the vendors in this market during the analysis period?

The emerging Asian-Pacific countries are projected to offer significant growth opportunities for the vendors in this market owing to the increasing prevalence of infectious and chronic diseases and the increasing awareness regarding disease risk prediction and a healthy lifestyle.